Advanced Kidney Cancer
5
0
1
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 5 trials
100.0%
+13.5% vs benchmark
20%
1 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Circulating and Urinary Exosomal miRNA in Advanced Kidney Cancer (EXO-RENAL1)
The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial.
Tislelizumab Plus Lenvatinib in Stage III-IV RCC
Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer
Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Kidney Cancer